Specialised proteins could halt cytokine storms in COVID-19 patients
Researchers who developed modified proteins say this could be used in the fight against COVID-19, by tackling cytokine storms.
List view / Grid view
Researchers who developed modified proteins say this could be used in the fight against COVID-19, by tackling cytokine storms.
An international consortium suggest that the severe symptoms of COVID-19, including Acute Respiratory Distress Syndrome (ARDS), could be caused by Neutrophil Extracellular Traps (NETs).
The developers of the lung epithelium model plan to investigate whether SARS-CoV-2 can infect and replicate in the model to assess whether it could be used in the fight against COVID-19.
A new report has revealed the vaccine R&D efforts of 15 of the leading pharmaceutical companies to combat the COVID-19 coronavirus.
Researchers working on related coronaviruses SARS and MERS have identified the membrane fusion peptide on the Spike protein as a possible drug target for SARS-CoV-2, the virus causing COVID-19.
The vaccine candidate protected all murine models from a lethal MERS infection and could also be effective against the SARS-CoV-2 virus causing COVID-19.
Researchers have created a new kind of immunotherapy using the interleukin-27 (IL-27) cytokine to effectively combat tumours in vitro and in vivo.
A potential COVID-19 vaccine has been developed by researchers using AI and cloud computing to prevent the Spike protein from binding to the ACE2 receptor on human cells.
ESHG 2019 Conference Presentation: Using KingFisher™ to increase reproducibility in new applications using challenging samples.
Two companies, Neurimmune and Ethris, will leverage their technologies to research, develop and produce an inhaled therapy for COVID-19.
The loss of RXR function, a molecular mechanism which determines the identity macrophages, has been revealed as a drug target for cancers in serous cavities.
Researchers have developed a vaccine against the COVID-19 coronavirus which induced the rapid production of antibodies in mice.
With the global ageing population at risk of death from influenza, what is pharma doing to develop more effective vaccines to combat the virus?
The University of Alabama at Birmingham (UAB) will run the pre-clinical trials of Altimmune’s intranasal COVID-19 vaccine candidate, AdCOVID.
A new CAR T-cell therapy has been created by researchers which targets three proteins on leukaemia cells and has shown success in pre-clinical trials.